IL131025A0 - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents
Treatment of autoimmune disease using tolerization in combination with methotrexateInfo
- Publication number
- IL131025A0 IL131025A0 IL13102598A IL13102598A IL131025A0 IL 131025 A0 IL131025 A0 IL 131025A0 IL 13102598 A IL13102598 A IL 13102598A IL 13102598 A IL13102598 A IL 13102598A IL 131025 A0 IL131025 A0 IL 131025A0
- Authority
- IL
- Israel
- Prior art keywords
- tolerization
- methotrexate
- treatment
- combination
- autoimmune disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3672297P | 1997-01-24 | 1997-01-24 | |
| PCT/US1998/001648 WO1998032451A1 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL131025A0 true IL131025A0 (en) | 2001-01-28 |
Family
ID=21890248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13102598A IL131025A0 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0994717A4 (en) |
| JP (1) | JP2001511134A (en) |
| KR (1) | KR20000070460A (en) |
| AU (1) | AU6648898A (en) |
| BR (1) | BR9807112A (en) |
| CA (1) | CA2278152A1 (en) |
| HU (1) | HUP0001960A2 (en) |
| IL (1) | IL131025A0 (en) |
| NO (1) | NO993600L (en) |
| WO (1) | WO1998032451A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1476210B1 (en) | 2002-02-11 | 2008-09-24 | Antares Pharma, Inc. | Intradermal injector |
| FI1850892T4 (en) | 2005-01-24 | 2023-08-31 | Prefilled needle assisted syringe jet injector | |
| GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
| WO2007131025A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injector with adjustable dosing |
| WO2007131013A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Two-stage reconstituting injector |
| EP2268342B1 (en) | 2008-03-10 | 2015-09-16 | Antares Pharma, Inc. | Injector safety device |
| EP2318075B1 (en) | 2008-08-05 | 2019-05-22 | Antares Pharma, Inc. | Multiple dosage injector |
| CN102612381B (en) | 2009-03-20 | 2015-09-09 | 安塔瑞斯制药公司 | Hazardous agents injected system |
| CN103002896A (en) | 2010-06-16 | 2013-03-27 | 布鲁斯·钱德勒·梅 | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
| EP4327849A3 (en) | 2012-03-06 | 2024-04-24 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
| EP4186545A1 (en) | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| WO2013169800A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| FI3659647T3 (en) | 2013-02-11 | 2024-03-28 | Antares Pharma Inc | Needle assisted jet injection device having reduced trigger force |
| ES2742046T3 (en) | 2013-03-11 | 2020-02-12 | Antares Pharma Inc | Dose injector with pinion system |
| WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
| JP2016512262A (en) | 2013-03-13 | 2016-04-25 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | Use of levocetirizine and montelukast in the treatment of vasculitis |
| EP3308835B1 (en) | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| ES2654093T3 (en) * | 2013-03-13 | 2018-02-12 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
| JP2017526728A (en) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | Levocetirizine and montelukast in the treatment of inflammation-mediated conditions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
| US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
| AU632991B2 (en) * | 1987-06-24 | 1993-01-21 | Autoimmune, Inc. | Treatment of autoimmune diseases by oral administration of autoantigens |
| EP0503055A1 (en) * | 1990-09-06 | 1992-09-16 | Rijksuniversiteit Utrecht | Inhibitor of lymphocyte response and immune-related disease |
| CA2117492C (en) * | 1992-02-28 | 2009-04-07 | Howard L. Weiner | Bystander suppression of autoimmune diseases |
| WO1996040235A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Method to use superantigens to target subpopulations of t cells |
| WO1996041644A1 (en) * | 1995-06-13 | 1996-12-27 | Nippon Meat Packers, Inc. | Oral remedy for rheumatoid arthritis and functional food |
-
1998
- 1998-01-26 CA CA002278152A patent/CA2278152A1/en not_active Abandoned
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/en not_active Application Discontinuation
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/en not_active Application Discontinuation
- 1998-01-26 IL IL13102598A patent/IL131025A0/en unknown
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/en unknown
- 1998-01-26 JP JP53225298A patent/JP2001511134A/en active Pending
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/en not_active Application Discontinuation
- 1998-01-26 EP EP98908452A patent/EP0994717A4/en not_active Withdrawn
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998032451A1 (en) | 1998-07-30 |
| CA2278152A1 (en) | 1998-07-30 |
| AU6648898A (en) | 1998-08-18 |
| HUP0001960A2 (en) | 2000-10-28 |
| JP2001511134A (en) | 2001-08-07 |
| NO993600L (en) | 1999-09-23 |
| BR9807112A (en) | 2001-09-18 |
| EP0994717A4 (en) | 2000-07-26 |
| KR20000070460A (en) | 2000-11-25 |
| NO993600D0 (en) | 1999-07-23 |
| EP0994717A1 (en) | 2000-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL131025A0 (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
| ZA989461B (en) | Methods and compositions for the treatment of autoimmune disease using heat shock proteins | |
| ZA9710339B (en) | Xanthines and their therapeutic use | |
| HUP0004439A3 (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
| ZA983452B (en) | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases. | |
| IL159785A0 (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
| EP0924983A4 (en) | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders | |
| EP0966386A4 (en) | Human powered vehicle | |
| IL144981A0 (en) | Treatment of autoimmune disease | |
| HUP0102142A3 (en) | Use of cyclosporins in the treatment of inflammatory autoimmune diseases | |
| HUP0001276A2 (en) | Illuminating body for swimming pools and similar | |
| HK1026096A1 (en) | Novel triptolide derivatives useful in the treatment of autoimmune diseases | |
| IL113303A0 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
| IL113301A0 (en) | Treatment of autoimmune disease using oral tolerization and/or TH2-enhancing cytokines | |
| HUP9900147A3 (en) | Therapeutic agents and autoimmune diseases | |
| GB9419553D0 (en) | Polypeptides and their use in the treatment of auto-immune disease | |
| HK1025954A1 (en) | Triptolide derivatives useful in the treatment of autoimmune diseases | |
| EP0797440A4 (en) | The treatment of autoimmune disease using 2-amino purine derivatives | |
| GB9621825D0 (en) | Microparticles and their use as therapeutic vehicles | |
| GB9705200D0 (en) | Well treatment with particles | |
| IL129460A0 (en) | Use of lofexidine in the treatment of behavioral disorders | |
| EP1073459A4 (en) | Compositions and methods for tolerization in immune complex-mediated disease progression | |
| AU7262800A (en) | Diagnostic and therapeutic methods in autoimmune disease | |
| EP1020517A4 (en) | Gene originating in human chondrocyte | |
| IL132845A0 (en) | Non-myeloablative tolerogenic treatment |